{"id":"methylphenidate","brandName":"Ritalin","genericName":"methylphenidate","companyId":"novartis","companyName":"Novartis","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":0,"mechanism":{"target":"Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor","_target_confidence":0.5},"administration":{"route":"Oral"},"safety":{"boxedWarnings":["WARNING: ABUSE AND DEPENDENCE C N S stimulants, including methylphenidate hydrochloride extended-release capsules , other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy [see Warnings and Precautions ( 5.1 ), Drug Abuse and Dependence ( 9.2 , 9.3 )] . WARNING: ABUSE AND DEPENDENCE See full prescribing information for complete boxed warning. CNS stimulants, including methylphenidate hydrochloride extended-release capsules , other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence ( 5.1 , 9.2 , 9.3 ). Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy ( 5.1 , 9.2 )."],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"7696 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"7501 reports"},{"date":"","signal":"NO ADVERSE EVENT","source":"FDA FAERS","actionTaken":"7019 reports"},{"date":"","signal":"PRODUCT QUALITY ISSUE","source":"FDA FAERS","actionTaken":"5586 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"3241 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"3114 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"3033 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"2918 reports"},{"date":"","signal":"DEPRESSION","source":"FDA FAERS","actionTaken":"2378 reports"},{"date":"","signal":"INSOMNIA","source":"FDA FAERS","actionTaken":"2372 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Appetite decreased","drugRate":"","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Weight decreased","drugRate":"","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Tic","drugRate":"","severity":"common","organSystem":""},{"effect":"Affect lability","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Application site reaction","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Irritability","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Skin erythema","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Aggressive behavior","Alcoholism","Anemia","Angina pectoris","Anorexia nervosa","Bipolar disorder","Blurring of visual image","Cardiomyopathy","Cerebrovascular accident","Chronic heart failure","Conduction disorder of the heart","Dependent drug abuse","Disorder of coronary artery","Epilepsy","Esophageal dysmotility","Feeling agitated","Gastrointestinal obstruction","Gilles de la Tourette's syndrome","Glaucoma","Hypertensive disorder","Hypertensive urgency","Hyperthyroidism","Leukopenia","Life-Threatening Cardiac Arrhythmias","Liver function tests abnormal","Lowered convulsive threshold","Mania","Mood swings","Motor tic disorder","Myocardial infarction","Myocardial infarction in recovery phase","Psychotic disorder","Seizure disorder","Severe anxiety (panic)","Short bowel syndrome","Sinus tachycardia","Structural disorder of heart","Substance abuse","Tension","Thrombocytopenic disorder","Thyrotoxicosis","Uncontrolled Epilepsy","Visual impairment"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Tics","drugRate":"1%","severity":"serious"},{"effect":"Application site reaction","drugRate":"2%","severity":"serious"}]},"trials":["NCT00783835","NCT01348607","NCT00917371","NCT06355414","NCT00773916","NCT00381758","NCT00526630","NCT02172183","NCT02247986","NCT07273695","NCT05685732","NCT02675400","NCT00424099","NCT00972985","NCT00852059","NCT01323192","NCT01183234","NCT04065906","NCT00730249","NCT06465641","NCT01552915","NCT01259492","NCT02501798","NCT02970500","NCT02020200","NCT05180149","NCT00220493","NCT01228604","NCT00499863","NCT06081179","NCT00025779","NCT02638168","NCT06580041","NCT04412499","NCT02293655","NCT00874536","NCT00758407","NCT00269776","NCT03595826","NCT00794040","NCT03511118","NCT00253747","NCT04333394","NCT05133804","NCT00418691","NCT00824317","NCT01835548","NCT00031798","NCT03511976","NCT01426984"],"indications":{"approved":[{"name":"Attention deficit hyperactivity disorder","diseaseId":"attention-deficit-hyperactivity-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Narcolepsy","diseaseId":"narcolepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[{"type":"Method of Use","number":"11166947","applicant":"NEOS THERAPEUTICS INC","territory":"US","tradeName":"COTEMPLA XR-ODT","expiryDate":"2038-01-25"},{"type":"Formulation","number":"9072680","applicant":"NEOS THERAPEUTICS INC","territory":"US","tradeName":"COTEMPLA XR-ODT","expiryDate":"2032-06-28"},{"type":"Formulation","number":"9089496","applicant":"NEOS THERAPEUTICS INC","territory":"US","tradeName":"COTEMPLA XR-ODT","expiryDate":"2032-06-28"},{"type":"Formulation","number":"8840924","applicant":"NEOS THERAPEUTICS INC","territory":"US","tradeName":"COTEMPLA XR-ODT","expiryDate":"2026-06-05"}],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT00783835","phase":"Phase 4","title":"A Multicenter Open Trial to Evaluate the Effectiveness and Quality of Life in Adults With Attention Deficit /Hyperactivity Disorder (ADHD) Treated With Long Acting Methylphenidate (CONCERTA)","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","isPivotal":false,"enrollment":60,"indication":"Attention Deficit Hyperactivity Disorder","completionDate":"2008-10"},{"nctId":"NCT01348607","phase":"Phase 2","title":"A Randomized, Phase II Placebo-controlled Study of the Use of Extended-release Methylphenidate or Modafinil for the Treatment of Excessive Daytime Sleepiness in Children Following Cancer Therapy","status":"TERMINATED","sponsor":"University of South Florida","isPivotal":false,"enrollment":1,"indication":"Central Nervous System Tumor, Pediatric, Fatigue","completionDate":"2012-12"},{"nctId":"NCT00917371","phase":"N/A","title":"The Effectiveness of Atomoxetine on Brain Imaging, Neuropsychological, and Social Functions in Adults With Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":60,"indication":"Attention Deficit Hyperactivity Disorder","completionDate":"2011-07-31"},{"nctId":"NCT06355414","phase":"Phase 1","title":"Psilocybin and Affective Function in Chronic Lower Back Pain Depression","status":"RECRUITING","sponsor":"Johns Hopkins University","isPivotal":false,"enrollment":40,"indication":"Chronic Low-back Pain, Depression","completionDate":"2026-08-30"},{"nctId":"NCT00773916","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Federal University of Rio Grande do Sul","isPivotal":false,"enrollment":130,"indication":"Attention Deficit Disorder With Hyperactivity","completionDate":"2009-07"},{"nctId":"NCT00381758","phase":"Phase 4","title":"A Randomized, Double-Blind Comparison of the Time Course of Response to Two Extended-Release Oral Delivery Systems for Methylphenidate in Pediatric Patients With Attention Deficit Hyperactivity Disord","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":false,"enrollment":184,"indication":"Attention Deficit Hyperactivity Disorder","completionDate":"2002-08"},{"nctId":"NCT00526630","phase":"Phase 4","title":"Methylphenidate for the Treatment of Gain Impairment in Parkinson's Disease: a Randomized Double-Blind, Placebo-Controlled, Cross-over Study","status":"COMPLETED","sponsor":"University of Cincinnati","isPivotal":false,"enrollment":23,"indication":"Parkinson's Disease, Gait Impairment","completionDate":"2009-10"},{"nctId":"NCT02172183","phase":"NA","title":"Group Therapy for Adolescents With Attention-Deficit/Hyperactivity Disorder: a Randomized Multicenter Controlled Trial","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","isPivotal":false,"enrollment":119,"indication":"Attention Deficit Hyperactivity Disorder","completionDate":"2014-05"},{"nctId":"NCT02247986","phase":"Phase 1","title":"Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder","status":"WITHDRAWN","sponsor":"National Institute of Mental Health (NIMH)","isPivotal":false,"enrollment":0,"indication":"Conduct Disorder, Attention Defict Hyperactivity Disorder","completionDate":"2015-05-18"},{"nctId":"NCT07273695","phase":"N/A","title":"Assessing Real Life Effectiveness of Treatment in Neurodevelopmental Disorders","status":"RECRUITING","sponsor":"IRCCS Eugenio Medea","isPivotal":false,"enrollment":80,"indication":"Emotional Dysregulation, Externalizing Problems","completionDate":"2026-12"},{"nctId":"NCT05685732","phase":"Phase 4","title":"A Multicenter, Dose-Optimized, Randomized, Double Blind, Efficacy and Safety Study With Azstarys® in Children 4 to 12 Years of Age With Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Corium, Inc.","isPivotal":false,"enrollment":246,"indication":"Attention Deficit/Hyperactivity Disorder","completionDate":"2024-05-02"},{"nctId":"NCT02675400","phase":"Phase 4","title":"Treatments for Fathers With Attention Deficit/Hyperactivity Disorder (ADHD) and Their At-Risk Children (Fathers Too)","status":"COMPLETED","sponsor":"Seattle Children's Hospital","isPivotal":false,"enrollment":19,"indication":"Attention Deficit/Hyperactivity Disorder (ADHD)","completionDate":"2018-08-31"},{"nctId":"NCT00424099","phase":"Phase 2","title":"A Randomized Controlled Trial of Methylphenidate and a Nursing Telephone Intervention (NTI) for Fatigue in Advanced Cancer Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":true,"enrollment":197,"indication":"Advanced Cancer, Fatigue","completionDate":"2021-11-22"},{"nctId":"NCT00972985","phase":"NA","title":"Acute Effect of Three Neuroactive Drugs on Brain Activity Measured by MEG, EEG and the Synchronous Neural Interaction Test","status":"COMPLETED","sponsor":"Orasi Medical, Inc.","isPivotal":false,"enrollment":15,"indication":"Healthy","completionDate":"2009-12"},{"nctId":"NCT00852059","phase":"Phase 4","title":"Effect of Methylphenidate Formulation on ADHD-patients' Adherence to Medical Treatment. A Comparison of Medikinet Retard® (ER) Once Daily and Medikinet® (IR) Twice Daily in Children and Adolescents Di","status":"TERMINATED","sponsor":"Prof. Huss","isPivotal":false,"enrollment":32,"indication":"ADHD","completionDate":"2013-12"},{"nctId":"NCT01323192","phase":"Phase 3","title":"A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","isPivotal":true,"enrollment":284,"indication":"Attention-Deficit Hyperactivity Disorder","completionDate":"2012-04"},{"nctId":"NCT01183234","phase":"Phase 1","title":"Phase 1,Randomized,Open-Label,Two Period Single Dose Crossover Bioequivalence Study of Two Capsule Strengths of SPD544 In Healthy Volunteers.","status":"COMPLETED","sponsor":"Shire","isPivotal":false,"enrollment":28,"indication":"ADHD","completionDate":"2010-10-22"},{"nctId":"NCT04065906","phase":"NA","title":"Near-infrared Spectroscopy Neurofeedback as a Treatment for Children With Attention Deficit Hyperactivity Disorder","status":"UNKNOWN","sponsor":"Xijing Hospital","isPivotal":false,"enrollment":90,"indication":"Neurofeedback, Attention Deficit Hyperactivity Disorder (ADHD)","completionDate":"2020-12-31"},{"nctId":"NCT00730249","phase":"Phase 3","title":"Quality Assurance of Administering Methylphenidate in Adults With ADHD","status":"COMPLETED","sponsor":"Medice Arzneimittel Pütter GmbH & Co KG","isPivotal":true,"enrollment":150,"indication":"Attention Deficit Hyperactivity Disorder","completionDate":""},{"nctId":"NCT06465641","phase":"Phase 4","title":"Effectiveness of Methylphenidate in Children and Adolescents With KBG Syndrome: An N-of-1 Series","status":"RECRUITING","sponsor":"Radboud University Medical Center","isPivotal":false,"enrollment":15,"indication":"Kbg Syndrome, ADHD - Combined Type","completionDate":"2027-10-01"},{"nctId":"NCT01552915","phase":"Phase 4","title":"A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo ","status":"COMPLETED","sponsor":"Shire","isPivotal":false,"enrollment":464,"indication":"Attention-deficit/Hyperactivity Disorder","completionDate":"2014-01-22"},{"nctId":"NCT01259492","phase":"Phase 3","title":"A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"enrollment":725,"indication":"Attention Deficit/Hyperactivity Disorder","completionDate":"2012-08"},{"nctId":"NCT02501798","phase":"Phase 4","title":"The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD: A Randomised Placebo Controlled Trial","status":"COMPLETED","sponsor":"VU University of Amsterdam","isPivotal":false,"enrollment":61,"indication":"Attention Deficit Hyperactivity Disorder","completionDate":"2016-05"},{"nctId":"NCT02970500","phase":"Phase 2","title":"Étude Pilote de Phase II Sur l'Effet du méthylphénidate Sur la Fonction Cognitive Des Patientes en rémission d'un Cancer du Sein","status":"TERMINATED","sponsor":"CHU de Quebec-Universite Laval","isPivotal":false,"enrollment":20,"indication":"Breast Cancer Female, Cancer-Related Condition","completionDate":"2022-12-31"},{"nctId":"NCT02020200","phase":"NA","title":"A Crossover Study on the Effect of Methylphenidate (MPH) on Cognitive Abilities of Adults With Bipolar Disorder (BD), During Remission or Depressed State, Compared With Healthy Adults and Adults With ","status":"UNKNOWN","sponsor":"Shalvata Mental Health Center","isPivotal":false,"enrollment":40,"indication":"BD","completionDate":""},{"nctId":"NCT05180149","phase":"N/A","title":"Personality and Drug Use (PDU)","status":"WITHDRAWN","sponsor":"Quantified Citizen Technologies Inc.","isPivotal":false,"enrollment":0,"indication":"Personality","completionDate":"2023-04"},{"nctId":"NCT00220493","phase":"Phase 1","title":"Clinical Study Protocol: Evaluation of the Efficiency of Ritalin in Multiple Sclerosis Patients","status":"UNKNOWN","sponsor":"Sheba Medical Center","isPivotal":false,"enrollment":80,"indication":"Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive","completionDate":"2005-06"},{"nctId":"NCT01228604","phase":"Phase 4","title":"COST-EFFECTIVENESS STUDY OF THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN BRAZIL","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","isPivotal":false,"enrollment":23,"indication":"Attention-deficit/Hyperactivity Disorder","completionDate":"2013-12"},{"nctId":"NCT00499863","phase":"Phase 3","title":"A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of MTS in Adolescents Aged 13-17 Years W","status":"COMPLETED","sponsor":"Noven Therapeutics","isPivotal":true,"enrollment":217,"indication":"ADHD","completionDate":"2008-05"},{"nctId":"NCT06081179","phase":"Phase 1","title":"Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans","status":"COMPLETED","sponsor":"University of Zurich","isPivotal":false,"enrollment":122,"indication":"Healthy","completionDate":"2025-09-22"},{"nctId":"NCT00025779","phase":"NA","title":"Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","isPivotal":false,"enrollment":60,"indication":"Attention Deficit Disorder With Hyperactivity, Autistic Disorder","completionDate":""},{"nctId":"NCT02638168","phase":"Phase 4","title":"Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With Attention Deficit Hyperactivity Disorder: A Randomized Placebo-controlled Pilot Study","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","isPivotal":false,"enrollment":3,"indication":"Attention Deficit Disorder With Hyperactivity, Behavioral Insomnia of Childhood","completionDate":"2018-06"},{"nctId":"NCT06580041","phase":"Phase 4","title":"Precision Care for Major Depressive Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":150,"indication":"Major Depressive Disorder, Depression","completionDate":"2029-09-01"},{"nctId":"NCT04412499","phase":"N/A","title":"Study of the Link Between Psychosocial Treatments and the Need of Pharmacological Treatments in Children With Attention Deficit Hyperactivity Disorder : a Retrospective Online Study for Parents","status":"COMPLETED","sponsor":"University Hospital, Montpellier","isPivotal":false,"enrollment":110,"indication":"Attention Deficit Hyperactivity Disorder, Youths","completionDate":"2020-06-30"},{"nctId":"NCT02293655","phase":"Phase 4","title":"The Effects of ADHD Medication (TEAM) Study: Neurobehavioral Effects of Abrupt Methylphenidate Discontinuation","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","isPivotal":false,"enrollment":204,"indication":"ADHD","completionDate":"2021-06-30"},{"nctId":"NCT00874536","phase":"NA","title":"The Effect of Omega-3 Fatty Acid Supplementation on Behavior of Children With ADHD","status":"COMPLETED","sponsor":"Hadassah Medical Organization","isPivotal":false,"enrollment":40,"indication":"Attention Deficit Hyperactivity Disorder","completionDate":"2011-06"},{"nctId":"NCT00758407","phase":"Phase 2","title":"Placebo Controlled Double Blind Study With Methylphenidate in Treatment of Adults With Cancer-Related Fatigue","status":"COMPLETED","sponsor":"Medice Arzneimittel Pütter GmbH & Co KG","isPivotal":true,"enrollment":66,"indication":"Cancer-related Fatigue","completionDate":""},{"nctId":"NCT00269776","phase":"Phase 3","title":"Screening, Efficacy, and Safety Study Evaluating OROS (Methylphenidate HCl), Ritalin and Placebo in Children With ADHD","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","isPivotal":true,"enrollment":0,"indication":"Attention Deficit Hyperactivity Disorder","completionDate":"1999-01"},{"nctId":"NCT03595826","phase":"NA","title":"The Effects of Exercise Therapy on the Co-Morbidity of Attention Deficit and Hyperactivity Disorder (ADHD) and Developmental Co-Ordination Disorder. (DCD)","status":"COMPLETED","sponsor":"University of KwaZulu","isPivotal":false,"enrollment":151,"indication":"Attention Deficit Disorder With Hyperactivity, Developmental Coordination Disorder","completionDate":"2019-05-30"},{"nctId":"NCT00794040","phase":"Phase 2","title":"A Controlled Trial of Citalopram Added to Methylphenidate in Youth With Severe Mood Dysregulation","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","isPivotal":false,"enrollment":103,"indication":"Mood Disorder, Mental Disorder Diagnosed in Childhood","completionDate":"2018-02-01"},{"nctId":"NCT03511118","phase":"N/A","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","isPivotal":false,"enrollment":1600,"indication":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","completionDate":"2027-07-31"},{"nctId":"NCT00253747","phase":"Phase 3","title":"A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers With ADHD","status":"COMPLETED","sponsor":"University of Cincinnati","isPivotal":true,"enrollment":255,"indication":"ADHD, Smoking","completionDate":"2008-03"},{"nctId":"NCT04333394","phase":"NA","title":"Investigating the Effectiveness of Probiotic Supplement in Improving Attention Deficit Hyperactivity Disorder Symptoms in Children","status":"UNKNOWN","sponsor":"National Nutrition and Food Technology Institute","isPivotal":false,"enrollment":40,"indication":"Attention Deficit Hyperactivity Disorder","completionDate":"2020-08"},{"nctId":"NCT05133804","phase":"Phase 2","title":"The Relation Between Attentional, Sensory and Emotional Dysregulation in Adults With Posttraumatic Stress Disorder: a Double-blind, Placebo-controlled Randomized Controlled Trial of the Combined Treat","status":"RECRUITING","sponsor":"University of Haifa","isPivotal":false,"enrollment":53,"indication":"Posttraumatic Stress Disorder","completionDate":"2025-12-01"},{"nctId":"NCT00418691","phase":"Phase 3","title":"Assessing the Efficacy of Immediate Release Methylphenidate, Sustained Release Methylphenidate and Modafinil for Patients With Brain Tumors","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","isPivotal":true,"enrollment":34,"indication":"Brain Tumor","completionDate":"2009-11"},{"nctId":"NCT00824317","phase":"NA","title":"Stimulant Drug Treatment of AD/HD, Inattentive Type","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","isPivotal":false,"enrollment":25,"indication":"ADHD","completionDate":"2005-02"},{"nctId":"NCT01835548","phase":"Phase 3","title":"A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Neos Therapeutics, Inc","isPivotal":true,"enrollment":87,"indication":"Attention Deficit Hyperactivity Disorder (ADHD)","completionDate":"2014-07"},{"nctId":"NCT00031798","phase":"Phase 3","title":"A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","isPivotal":true,"enrollment":0,"indication":"Brain and Central Nervous System Tumors, Cognitive/Functional Effects","completionDate":"2006-05-01"},{"nctId":"NCT03511976","phase":"Phase 4","title":"Adaptive Response to Intervention (RTI) for Students With ADHD","status":"WITHDRAWN","sponsor":"Florida International University","isPivotal":false,"enrollment":0,"indication":"Attention Deficit Disorder With Hyperactivity","completionDate":"2023-10-21"},{"nctId":"NCT01426984","phase":"NA","title":"A Double Blind Crossover Study on the Effect of Methylphenidate on Decision-making Ability of Adults With Borderline Personality Disorder (BPD) Compared to Adults With Attention Deficit Hyperactivity ","status":"UNKNOWN","sponsor":"Shalvata Mental Health Center","isPivotal":false,"enrollment":20,"indication":"Borderline Personality Disorder","completionDate":"2013-05"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$3.2359/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,181","description":"METHYLPHENIDATE 10 MG CHEW TAB","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-05-06T00:00:00.000Z","mah":"AYTU BIOPHARMA","brand_name_local":null,"application_number":"NDA021259"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-02-25T00:00:00.000Z","mah":"NOVEL LABS INC","brand_name_local":null,"application_number":"ANDA204115"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-10-28T00:00:00.000Z","mah":"SPECGX LLC","brand_name_local":null,"application_number":"ANDA202608"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-09-06T00:00:00.000Z","mah":"TRIS PHARMA INC","brand_name_local":null,"application_number":"ANDA091601"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-09-12T00:00:00.000Z","mah":"HIBROW HLTHCARE","brand_name_local":null,"application_number":"ANDA210139"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8840924","territory":"US","patent_type":"Formulation","expiry_date":"2026-06-05T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9072680","territory":"US","patent_type":"Formulation","expiry_date":"2032-06-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9089496","territory":"US","patent_type":"Formulation","expiry_date":"2032-06-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11166947","territory":"US","patent_type":"Method of Use","expiry_date":"2038-01-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":2,"withResults":1},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=methylphenidate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:16:40.693919+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:16:40.693847+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:16:46.778149+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:16:39.815256+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=methylphenidate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:16:46.977522+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:16:35.714059+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: ABUSE AND DEPENDENCE C N S stimulants, including methylphenidate hydrochloride extended-release capsules , other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy [see Warnings and Precautions ( 5.1 ), Drug Abuse and Dependence ( 9.2 , 9.3 )] . WARNING: ABUSE AND DEPENDENCE See full prescribing information for complete boxed w","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:16:35.714088+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:16:48.503242+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Norepinephrine transporter inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:16:48.012833+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL796/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:16:47.676529+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA079031","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:16:35.714093+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:16:51.569567+00:00","fieldsConflicting":1,"overallConfidence":0.8},"crossReferences":{"chemblId":"CHEMBL796"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}